Printer Friendly

CYTOGEN ANNOUNCES FIRST QUARTER RESULTS

 CYTOGEN ANNOUNCES FIRST QUARTER RESULTS
 PRINCETON, N.J., April 21 /PRNewswire/ -- Cytogen Corp.


(NASDAQ: CYTO) today reported total revenues for the 13-week period ended March 28, 1992, of $5.2 million, a significant increase in comparison to $1.1 million for the comparable period in 1991. The revenues included a one-time licensing fee of $3.0 miion was realized from the sale of research services, $1.0 million in interest income, and $138,000 from product related sources.
 In commenting on these results, Martin D. Cleary, group vice president and chief financial officer, said, "Cytogen's excellent first quarter performance includes two important new ongoing sources of revenue. CytoRad will provide Cytogen with funding for the prostate and bladder product development programs. In addition, we have recognized the first revenue due Cytogen from the initial sales of OncoScint(R) colorectal launched in four European countries during the first quarter by EuroCetus, N.V. With the required medical education process sales are expected to build gradually, early feedback from Europe indicates the product is being well received, and it is making contributions to patient management."
 The company's operating expenses of $7.1 million for the 13-week period ended March 28, 1992, were 27 percent above the $5.6 million incurred during the comparable period in 1991. Research and development expenses principally associated with product development efforts increased to $5.4 million, as compared to $4.5 million in 1991. Marketing, general and administrative expenses increased to $1.7 million in 1992 from $1.1 million in the first quarter of 1991 reflecting greater activity in preparation for the U.S. launch of the OncoScint colorectal and ovarian products.
 The net loss of $2.0 million for the 13-week period ended March 28, 1992, was 56 percent below the net loss of $4.5 million incurred during the same period in 1991. The loss per common share in 1992 was $.13 on 18.4 million average shares outstanding in comparison to $.31 per share on 15.9 million average shares outstanding for the same period in 1991.
 Cytogen Corporation is a biopharmaceutical company which has developed proprietary systems for linking drugs and diagnostic agents to monoclonal antibodies in order to optimize the function of the antibody as a delivery vehicle. The company currently has six cancer imaging agents under development and two of these imaging agents, for colorectal and ovarian cancer, are awaiting FDA marketing approval. Also in clinical development are two cancer therapy agents. The products being developed include those licensed to CytoRad.
 CYTOGEN CORPORATION
 First Quarter Ended March 28, 1992
 (Unaudited; In thousands except per-share data)
 Balance Sheet March 28, 1992 Dec. 28, 1991
 Assets:
 Cash and short-term investments $50,471 $54,506
 Other current assets 4,137 3,325
 Inventory 3,562 1,668
 Property and equipment 5,026 4,872
 Other assets 100 100
 Total assets 63,296 64,471
 Liabilities and Stockholders' Equity:
 Current liabilities $6,974 $6,115
 Deferred charges 270 346
 Preferred stock 17,245 17,250
 Redeemable common stock 2,000 2,000
 Common stock and accumulated deficit 36,807 38,760
 Total liabilities and
 stockholders' equity 63,296 64,471
 Statement of Operations
 (Unaudited)
 13 weeks ended March 28, 1992 March 30, 1991
 Total revenues $5,160 $1,149
 Operating expenses 7,134 5,626
 Net loss (1,974) (4,477)
 Net loss per common share ($0.13) ($.31)
 Weighted average common
 shares outstanding 18,387 15,859
 /delval/
 -0- 4/21/92 R
 /CONTACT: Laura M. Hahn of Cytogen, 609-987-8221/
 (CYTO) CO: Cytogen Corporation ST: New Jersey IN: MTC SU: ERN


JS-MK -- PH002 -- 0568 04/21/92 11:15 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 21, 1992
Words:607
Previous Article:AIR CANADA EXTENDS VALIDITY DATES OF ITS SPECIAL BIRTHDAY FARES
Next Article:ADOBE RESOURCES AND SANTA FE ENERGY RESOURCES TO DISMISS LAW SUIT


Related Articles
CYTOGEN ANNOUNCES FIRST QUARTER RESULTS
CYTOGEN CORPORATION ANNOUNCES FOURTH QUARTER AND ANNUAL RESULTS
CYTOGEN UPDATES STOCKHOLDERS ON MARKETING OF ONCOSCINT(R) CR/OV, PRODUCT DEVELOPMENT ACTIVITIES & CYTORAD DEVELOPMENTS
CYTOGEN CORPORATION ANNOUNCES FIRST QUARTER RESULTS
CYTOGEN CORPORATION REPORTS ON DEVELOPMENTS CONNECTED WITH SEC FILING
CYTOGEN REPORTS YEAR END RESULTS AND CITES DECREASE IN 1994 OPERATING EXPENSES
CYTOGEN CORPORATION ANNOUNCES UPDATE ON FIRST QUARTER ACHIEVEMENTS AND FINANCIAL RESULTS
/C O R R E C T I O N -- CYTOGEN/(Correction Notice)
Cytogen Reports Record Product Revenues in the First Quarter of 2004 and Reaffirms 2004 Full Year Financial Guidance; Year-Over-Year Growth From Both...
Cytogen Reports First Quarter 2006 Financial Results.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters